Suchergebnisse - "Vallet, Sonia"

PubPharm (135)

71

CCR1 as a target for multiple myeloma

enthalten in: Expert opinion on therapeutic targets | 2011

von Vallet, S. | Anderson, K.

72

CCR1 as a target for multiple myeloma

enthalten in: Expert opinion on therapeutic targets | 2011

von Vallet, S. | Anderson, K.

73

Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2011

von Santo, L. | Hideshima, T. | Cirstea, D. | +15

74

Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide

enthalten in: Clinical cancer research | 2011

von Santo, L. | Hideshima, T. | Cirstea, D. | +15

75

CCR1 as a target for multiple myeloma

enthalten in: Expert opinion on therapeutic targets | 24 May 2011

von Vallet, S. | Anderson, K.

76

A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function

enthalten in: Leukemia | 15 March 2011

von Vallet, S. | Pozzi, S. | Patel, K. | +9

77

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment : therapeutic implications

enthalten in: British journal of haematology | 19 September 2011

von Podar, K. | Zimmerhackl, A. | Fulciniti, M. | +10

78

Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss

enthalten in: Current opinion in molecular therapeutics | 2010

von Raje, N. | Vallet, S.

79

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma

enthalten in: Blood | 2010

von Ikeda, H. | Hideshima, T. | Fulciniti, M. | +17

80

PI3K/p110δ is a novel therapeutic target in multiple myeloma

enthalten in: Blood | 2010

von Ikeda, H. | Hideshima, T. | Fulciniti, M. | +17